Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAL 0891

Next Previous
Drug Profile

BAL 0891

Alternative Names: BAL-0891; TTK/PLK1 inhibitor

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Netherlands Translational Research Center
  • Developer Basilea Pharmaceutica; SillaJen Biotherapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 02 Jun 2026 Adverse events and pharmacokinetics data from phase I trial in Solid tumor presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 29 May 2026 Pharmacokinetics, adverse evenet and pharmacodynamics data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASCO-2026)
  • 28 Jan 2026 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in South Korea (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top